FDA Releases Guidance on CGT Early-Stage Trials

Thursday, June 18, 2015


Because cellular and gene therapy products can have more severe effects than other types of drug products, potentially leading to organ failure, tumors or death, sponsors should include these as primary safety objectives when designing early-phase clinical trials, the FDA says.

View All News »